secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001193125-25-264707
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx Q3 revenue $160M (+15% YoY); sells 25% Crysvita royalty for $400M
----------------------------------------------------------------------------

- Total revenue $160M (+15% YoY); Crysvita $112M, Dojolvi $24M, Evkeeza $17M.
- Net loss $180M ($1.81/share) vs $134M ($1.40) in Q3 2024; operating expense $331M.
- Received $400M from OMERS for additional 25% Crysvita royalty; repurchase option at $540M.
- FY2025 guidance reaffirmed: total rev $640-670M, Crysvita $460-480M, Dojolvi $90-100M.
- UX143 OI Phase 3 data expected year-end; DTX401 BLA submission on track for Q4 2025; UX111 BLA resubmission early 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000119312525264707/0001193125-25-264707-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000119312525264707/rare-20251103.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-264707

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer